Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corporation (Nasdaq: LUNG) is a commercial-stage medical technology company described as a global leader in minimally invasive treatments for lung disease, with a focus on chronic obstructive pulmonary disease (COPD) and severe emphysema. The LUNG news page on Stock Titan aggregates company press releases and market updates so readers can follow how Pulmonx’s business and capital markets profile evolve over time.
News about Pulmonx often centers on financial results, including quarterly revenue, gross margin, operating expenses, net loss, and non-GAAP metrics such as Adjusted EBITDA and constant currency revenue growth. Earnings releases also discuss revenue trends between the United States and international markets, reflecting adoption of Zephyr Valve procedures and related technologies in more than 25 countries.
Another recurring theme in Pulmonx news is clinical and commercial progress for the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. The company highlights the Zephyr Valve’s FDA pre-market approval following its designation as a “breakthrough device,” its inclusion in global treatment guidelines, and its role as a standard of care option for certain severe emphysema patients.
Investors and observers will also find corporate governance and leadership updates reported through press releases and corresponding Form 8-K filings, such as the reappointment of Glen French as President and Chief Executive Officer and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. Additional news items cover participation in healthcare and growth investor conferences, where management presents Pulmonx’s story to the investment community.
By reviewing the LUNG news feed, readers can track Pulmonx’s reported financial performance, executive transitions, equity inducement grants, and investor outreach activities, all of which provide context for understanding the company’s progress in the COPD and emphysema treatment market.
Pulmonx Corporation (Nasdaq: LUNG) will announce its third-quarter 2022 financial results on November 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Pulmonx specializes in minimally invasive treatments for lung disease, particularly through its FDA-approved Zephyr® Endobronchial Valve, which has been used in over 25,000 patients globally. Interested parties are encouraged to register online for the call, which will also be available via live and archived webcast.
Pulmonx Corporation (NASDAQ: LUNG) reported promising interim results from the CONVERT clinical trial presented at the 2022 European Respiratory Society (ERS) International Conference. The trial demonstrated that the AeriSeal System successfully closed collateral air channels in 78% of patients with severe COPD/emphysema, making them eligible for Zephyr Endobronchial Valves. Notable improvements were observed in lung function (FEV1 increase of 19.7%), quality of life (SGRQ score decrease of 15.1), and exercise capacity (Six-Minute Walk Distance increase of 77.2 meters).
Pulmonx Corporation (NASDAQ: LUNG) has announced promising interim results from the CONVERT Study presented at the 2022 European Respiratory Society Conference. The study indicates that the AeriSeal System successfully converted collateral ventilation status in 78% of patients, enabling them to receive Zephyr Valves treatment. The trial demonstrated a mean Target Lobe Volume Reduction of over 1 liter, improving lung function by 19.7%, quality of life, and exercise capacity. No serious adverse reactions were noted in recent studies, marking a significant advancement in the treatment of severe COPD.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, announced its participation in two upcoming investor conferences. The company will speak at the Wells Fargo Healthcare Conference in Boston on September 7, 2022, at 6:10 AM PT/9:10 AM ET, and the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 13, 2022, at 1:40 PM PT/4:40 PM ET. A live webcast of the presentations will be accessible on Pulmonx’s investor website.
Pulmonx reported strong Q2 2022 results with worldwide revenue reaching $14.0 million, a 14% increase year-over-year. U.S. revenue surged 31% to $8.6 million, driven by Zephyr Valve procedures. Gross margin improved to 75%, up from 74% in Q2 2021. However, operating expenses rose 14% to $24.8 million, contributing to a net loss of $14.6 million or $0.40 per share. Pulmonx maintains its full-year revenue guidance of $55-$60 million.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible on the company's Investors page. Pulmonx is known for its Zephyr® Endobronchial Valve, which has treated over 25,000 patients worldwide, and received FDA premarket approval as a breakthrough device.
Pulmonx Corporation (NASDAQ: LUNG) will announce its Q2 2022 financial results on August 2, 2022, after market close. A conference call will be held at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. Pulmonx is a leader in minimally invasive treatments for lung disease, notably through its FDA-approved Zephyr® Endobronchial Valve, which is available in over 25 countries. The company has treated more than 25,000 patients with over 100,000 valves used.
Pulmonx Corporation (LUNG) reported Q1 2022 financial results, highlighting a 17% increase in worldwide revenue to $10.8 million compared to Q1 2021. U.S. revenue surged 40% to $6.0 million, driven by growth in Zephyr Valve procedures. Gross margin improved to 75%, up from 72%, despite operating expenses rising 24% to $23.8 million. The net loss for the quarter was $15.8 million, or $0.43 per share. Pulmonx maintains its 2022 revenue outlook of $55 million to $60 million amidst ongoing investments and challenges from COVID and foreign exchange rates.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 12:40 PM PT. A live and archived webcast will be available on the company's investor website. Pulmonx is known for its innovative Zephyr Valve, which treats patients with severe emphysema/COPD and has received FDA breakthrough device designation. The valve is commercialized in over 25 countries, with more than 100,000 units used to date.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q1 2022 financial results on May 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can participate by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 2575271. The event will also be accessible via a live and archived webcast on the company's website.